Spironolactone vs Oral Minoxidil for Women

If you are a woman with pattern hair loss (female pattern hair loss, or FPHL), your dermatologist will likely discuss two oral medications: spironolactone and low-dose oral minoxidil (LDOM). Both are prescribed off-label for hair loss, both have growing evidence behind them, and both produce measurable results in clinical studies. But they work through entirely different mechanisms, carry different side effect profiles, and suit different patient profiles. Understanding these differences helps you choose a starting point, set accurate expectations, and build a tracking plan that captures the right signals at the right times.

Track your medication response from month one

HairLossTracker gives you a structured photo and symptom log for spironolactone, oral minoxidil, or both. Compare monthly progress and bring clear visual data to your dermatologist follow-ups.

Use the BaldingAI hair tracking app to save one baseline session now, compare monthly checkpoints later, and keep one clear record for your next treatment or dermatologist decision.

Start Tracking In BaldingAITry free tools or compare the app first

How each medication works

Spironolactone: blocking the hormonal driver

Spironolactone is an anti-androgen. It was originally developed as a potassium-sparing diuretic for blood pressure management, but dermatologists discovered it reduces androgen activity at the cellular level. It works through two mechanisms: blocking androgen receptors on hair follicle cells so DHT and testosterone cannot bind, and partially inhibiting 5-alpha reductase (the enzyme that converts testosterone to DHT). The typical dose for FPHL is 100-200mg per day.

Because FPHL is driven by androgen sensitivity at the follicle level (even in women with normal androgen blood levels), blocking androgen signaling addresses the root mechanism. Spironolactone does not stimulate new hair growth directly. It slows or halts the miniaturization process, giving follicles a chance to recover their normal growth cycle over time. This is why results take 6-12 months to become visible. The follicles need several growth cycles without androgen-driven miniaturization before they produce thicker, longer hairs again.

Oral minoxidil: stimulating growth directly

Oral minoxidil is a vasodilator. It was developed as an antihypertensive medication, and one of its most notable side effects was hair growth across the body, which led to the development of topical minoxidil for hair loss. Low-dose oral minoxidil (typically 0.625-2.5mg for women, compared to the 10-40mg used for blood pressure) promotes hair growth through multiple pathways: increasing blood flow to hair follicles, opening potassium channels that prolong the anagen (growth) phase, and stimulating vascular endothelial growth factor (VEGF) production.

Unlike spironolactone, oral minoxidil does not address the androgen-driven cause of FPHL. It stimulates growth regardless of the underlying mechanism, which makes it effective for multiple types of hair loss (FPHL, telogen effluvium, alopecia areata). Results tend to appear faster than spironolactone, with many patients noticing changes by 3-6 months. For a detailed month-by-month breakdown, see the oral minoxidil timeline and side effect tracking guide.

Efficacy: what the studies show

Sinclair et al. (2005, Journal of the American Academy of Dermatology) studied spironolactone in 80 women with FPHL over 12 months. At 200mg/day, 44% of patients showed improvement in hair loss severity. An additional 44% showed stabilization (no further progression). Only 12% continued to decline. The study noted that improvement was gradual and most apparent after 6-12 months of consistent use.

For oral minoxidil, Sinclair et al. (2022, JAMA Dermatology) conducted a randomized, double-blind, placebo-controlled trial of 0.25mg vs. 1.25mg LDOM in 30 women with FPHL. At 6 months, the 1.25mg group showed significant increases in hair density compared to baseline. The study was small but methodologically strong. A larger retrospective study by Vano-Galvan et al. (2021, Journal of the American Academy of Dermatology) reviewed 1,404 patients on LDOM and found that 60-65% reported improvement, with 1.25mg being the most commonly prescribed dose for women.

Direct head-to-head trials comparing the two medications are limited. Based on available data, oral minoxidil may produce slightly more visible regrowth in the short term (3-6 months), while spironolactone provides better long-term stabilization by addressing the hormonal cause. Neither is dramatically superior to the other, and individual response varies significantly.

Side effect profiles

Spironolactone side effects

• Hyperkalemia: Spironolactone causes potassium retention. Potassium levels must be monitored via blood tests, particularly in the first few months and in patients with kidney issues. This is the most medically significant risk.
• Menstrual irregularity: Common at higher doses (150-200mg). Periods may become irregular, lighter, or heavier. This often stabilizes after 2-3 months.
• Breast tenderness: Reported in roughly 10-15% of patients due to the anti-androgen effect.
• Dizziness and low blood pressure: More likely at higher doses and during the first few weeks. Starting at a lower dose (50-100mg) and titrating up reduces this risk.
• Pregnancy contraindication: Spironolactone is absolutely contraindicated in pregnancy. It can cause feminization of a male fetus. Reliable contraception is required.

For a full timeline of what to expect month by month, see the spironolactone results timeline and tracking guide.

Oral minoxidil side effects

• Hypertrichosis: The most common side effect. 15-20% of women on LDOM develop increased facial or body hair growth. This is dose-dependent and typically manageable with hair removal methods, but it is the primary reason some patients discontinue.
• Ankle edema: Fluid retention, usually mild, reported in approximately 5-10% of patients at low doses.
• Headache: Related to the vasodilatory effect. Usually transient and resolves within the first 2-4 weeks.
• Heart rate increase: A slight increase in resting heart rate (5-10 bpm) can occur. Patients with pre-existing cardiac conditions need ECG monitoring.
• Pericardial effusion: Extremely rare at low doses used for hair loss (0.625-2.5mg), but documented at the higher doses used for blood pressure (10-40mg). An echocardiogram may be recommended before starting treatment in patients with cardiac risk factors.

Who benefits most from which medication

Spironolactone may be the better first choice if: you have signs of androgen excess (acne, oily skin, hirsutism, irregular periods), your FPHL follows a clear hormonal pattern (widening central part, frontal thinning), you also have PCOS or elevated androgen levels on blood work, or you want to address the underlying hormonal driver rather than just stimulate growth.

Oral minoxidil may be the better first choice if: your androgen levels are normal and there are no other signs of androgen excess, you have diffuse thinning that does not follow a classic hormonal pattern, you want faster visible results (3-6 months vs. 6-12 months), you have tried topical minoxidil and found it effective but difficult to apply consistently, or your hair loss involves components beyond FPHL (such as residual telogen effluvium).

Combining spironolactone and oral minoxidil

Because the two medications work through independent mechanisms, combining them is logical and increasingly common in clinical practice. Randolph and Tosti (2021, Journal of the American Academy of Dermatology) noted that combination therapy can provide both hormonal blockade (spironolactone) and direct growth stimulation (minoxidil) simultaneously. This is similar to how men often combine finasteride (anti-androgen) with minoxidil for superior results.

A typical combination approach: start with one medication, track results for 6 months, then add the second if results are partial. This staggered start helps you identify which medication is contributing what effect, and it isolates any side effects to a single variable. If you start both simultaneously and develop a side effect, you cannot determine which drug caused it without stopping one.

Monitoring requirements

• Spironolactone: Baseline blood work (potassium, kidney function, blood pressure). Repeat potassium check at 4-6 weeks, then every 3-6 months. Pregnancy test before starting. Reliable contraception throughout use.
• Oral minoxidil: Baseline blood pressure and heart rate. Some dermatologists request a baseline ECG and/or echocardiogram, especially for patients over 40 or with cardiac risk factors. Blood pressure checks at 2-4 weeks, then every 3-6 months.
• Both combined: All of the above. Spironolactone can cause low blood pressure and minoxidil can lower it further, so monitoring is especially important during the first month of combination therapy.

Tracking plan: what to document

Regardless of which medication you choose, structured tracking turns subjective feelings ("I think it might be working") into objective data. Use the spironolactone tracking plan or the oral minoxidil tracking plan as your framework.

• Baseline photos (week 0): Top-down part line, frontal hairline, and crown. Same lighting, same distance, same hair state (dry, unstyled). These are the images you will compare everything against.
• Monthly photos (months 1-6): Same angles, same conditions. Expect little visible change in the first 2-3 months with either medication. Do not panic and do not quit early based on photos alone.
• Side effect log: Record any new symptoms with dates and severity. Note menstrual changes (spironolactone), facial hair growth (minoxidil), dizziness, headaches, or ankle swelling. This log is essential for dosage adjustment conversations with your doctor.
• Shedding observations: Both medications can cause an initial shedding phase (more pronounced with minoxidil). Counting hairs lost during washing on a consistent schedule gives you trend data rather than daily anxiety triggers.
• 6-month comparison: This is the first meaningful checkpoint for both medications. Place baseline and month-6 photos side by side. Look at part width, density along the hairline, and overall coverage.

For a broader view of tracking strategies and tools, explore the hair loss tracking blog. Consistent documentation makes every follow-up appointment more productive and helps your dermatologist fine-tune your treatment based on real data rather than memory.

Frequently asked questions

Which is better for women's hair loss: spironolactone or oral minoxidil?

Neither is universally better. Spironolactone is often preferred for women with signs of androgen excess (acne, hirsutism, PCOS) because it targets the hormonal cause. Oral minoxidil may produce faster visible results and works regardless of hormonal status. Your dermatologist can help determine which is more appropriate based on your blood work, symptoms, and hair loss pattern.

Can you take spironolactone and oral minoxidil together?

Yes. Many dermatologists prescribe both for women with FPHL. The medications work through independent mechanisms (anti-androgen vs. growth stimulation), so combining them can provide complementary benefits. Blood pressure monitoring is important because both can lower blood pressure. A staggered start (beginning one medication, then adding the second after 3-6 months) helps isolate side effects and determine individual contributions to your results.

How long does spironolactone take to work for hair loss?

Most patients need 6-12 months to see visible improvement. Spironolactone works by blocking androgen activity, which halts further miniaturization. Existing miniaturized follicles then need several growth cycles (each cycle lasting 3-6 months) to produce progressively thicker hair. Reduced shedding is often the first noticeable sign, typically by month 3-4, with visible density improvement following later.

What dose of oral minoxidil is used for female hair loss?

The most commonly prescribed dose is 0.625-2.5mg per day, with 1.25mg being the most frequent starting point. These doses are far lower than the 10-40mg used for blood pressure management, which substantially reduces the risk of cardiovascular side effects. Your dermatologist may start at 0.625mg and increase gradually based on your response and tolerance. Higher doses within this range produce more growth but also increase the likelihood of hypertrichosis (unwanted body and facial hair).